Marketscan claims study of 62,813 IMID women w/ 70,529 pregnancies & 69,412 births, 4,485 (7.1%) were exposed to at least one TNFi during pregnancy & 3,559 postpartum. TNFi use NOT assoc w/ SIE risk during Preg (HR 1.39; 0.95-2.05) or postpartum (HR 1.22; https://t.co/NsxOLpT0ds

💬 #ACR25 Topic Panels — LIVE! Nov. 5 join RheumNow at 7 PM ET for a deep dives into the hottest topics in rheumatology: 👉 SpA Join Us Live on: X • Facebook • YouTube • LinkedIn • https://t.co/V10S4oVFsv Top experts. Real clinical insight. Don't miss these discussions https://t.co/ARrEpN2ybC

• Home | RheumNow

GLP-1 and SGLT-2: Treatments Too Good to Ignore? Dr. Peter Nash reviews several studies presented on GLP-1s at #ACR25. He recommends for review abstracts: 0841, 0849, 1027, 2685, 0165, 0233 and 2658. https://t.co/OclO05bpku https://t.co/kASID9jnAP

• GLP-1 and SGLT-2: Treatments Too Good to Ignore? | RheumNow

B Cell Depletion: Check the Lymph Node Dr. Akhil Sood reports on abstract 2695 (B-cell depletion and lymphoid follicle disruption upon different B-cell depleting agents) presented at #ACR25. https://t.co/BjgIC3Kng0 https://t.co/flfyLZYW8q

• B Cell Depletion: Check the Lymph Node | RheumNow

🌟 Wonderful news! One of the EMEUNET Top 10 Abstracts ACR 2025 has been accepted on Rheumatology! 🎊 Congratulations Erdem Bektas (@ebektasmd ) for this achievement! 👉You can read the manuscript in this link: https://t.co/teEscaBVG3 #EMEUNET https://t.co/BKRXTXiQ8U

• Clinical significance of non-infectious procalcitonin elevation in Still’s dise…
• https://x.com/EMEUNET/status/1985738861666799816/photo/1

Join us as we celebrate & congratulate, Eric L. Matteson, MD, MPH, recipient of the 2025 ACR Presidential Gold Medal Award! 🌟 VIEW → https://t.co/ZcIXeZbAKr @MayoClinic #ACR25 https://t.co/7G07K7ZkjS

• 2025 ACR Presidential Gold Medal Award – Eric L. Matteson, MD, MPH
• https://x.com/ACRheum/status/1985754441945899516/photo/1

🆕 Clinical Year in Review at #ACR25 By Dr. Bryant England @UNMC_Rheum 🔶 Review the most impactful studies in #Rheumatology from the past year! ❓ Any studies you would add to the list? #RheumX #RheumTwitter #ACR2025 https://t.co/rgOb4ZV4r8

• https://x.com/MithuRheum/status/1983592853105471969/photo/1

This and other reports on palindromic rheumatism show that PR is a pre-clinical RA state, both having same predictive factors for progression to RA! https://t.co/jfpraGfe72

• https://twitter.com/RichardPAConway/status/1983206625205793213

Psoriatic Arthritis: Which biologic agent is the best first choice? A growing arsenal of therapeutic targets in psoriatic arthritis (PsA) has enhanced the landscape of treatment in patients with this disease. https://t.co/pRMyPCvMrN https://t.co/nOgnf5F3Pw

• Psoriatic Arthritis: Which biologic agent is the best first choice? | RheumNow

Should we be using JAKi more in female SpA patients? In recent years, data has emerged suggesting that female patients with spondyloarthritis, both psoriatic arthritis and axial spondyloarthritis, may have worse outcomes than male patients. A number of post-hoc analyses of https://t.co/smLao0q2hv

💬 #ACR25 Topic Panels — LIVE! Nov. 4 join RheumNow at 7 PM ET for a deep dives into the hottest topics in rheumatology: CAR-T Join Us Live on: X • Facebook • YouTube • LinkedIn • https://t.co/V10S4oVFsv Top experts. Real clinical insight. Don't miss these discussions https://t.co/zedho2RI6T

• Home | RheumNow